Cidara Therapeutics

Our CEO, Jeffrey Stein, Ph.D., spoke with Luke Timmerman on The Long Run podcast about our Cloudbreak platform and novel drug-Fc conjugate (DFC) candidate that has the potential for universal protection against all seasonal and pandemic #influenza A and B strains. Listen to the full podcast here: https://lnkd.in/gBUZz32T

Did you know our first-in-class antiviral drug-Fc conjugate (DFC) candidate has demonstrated universal activity across #influenza A and B viruses, including potent activity against #H5N1 in preclinical studies? Read more here: https://bit.ly/3XgCzXA

Today, we announced that we will be presenting a poster at ASM Microbe 2024, taking place from June 13-17, 2024, at the Georgia World Congress Center in Atlanta. Read the full press release here: https://lnkd.in/gXwyyz2n American Society for Microbiology

Read more about our recent $240M private placement financing led by RA Capital and reacquisition of CD388, our lead drug-Fc conjugate (DFC) candidate, in this blog post from Laura Tadvalkar, Managing Director on the Venture Team at RA Capital: https://brnw.ch/21wJhPq

Today, we announced two poster presentations highlighting Phase 1 and Phase 2a clinical data on our drug candidate, CD388, at the 34th ESCMID - European Society of Clinical Microbiology and Infectious Diseases Conference in Barcelona, Spain, from April 27 to 30. Read the full press release here: https://brnw.ch/21wJd1g

Today we announced our reacquisition of exclusive global development and commercial rights to CD388 from Johnson & Johnson, our $240M private placement financing and our divestiture of rezafungin to Mundipharma. Listen to our webcast at 4:30pm ET today for more info: https://brnw.ch/21wJ962

We're excited to share new data on our multispecific CD73/PD-1 drug-Fc conjugate (DFC), our CCR5-targeting DFC and CBO421, our lead oncology DFC candidate, at the American Association for Cancer Research (AACR) Annual Meeting. Read the full details of our presentations here: https://brnw.ch/21wIyHY #AACR24

We’ll be presenting four posters, including one late-breaking poster, on our novel drug-Fc conjugates (DFCs) at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, April 5-10. Find more details about our presentations here: https://brnw.ch/21wHCs2 #AACR24

Today we announced receipt of an ~$11 million milestone payment from Mundipharma following European approval of our invasive candidiasis drug in adult patients. Read the press release: https://brnw.ch/21wGTHJ

Today our treatment for adults with invasive candidiasis has been approved by the United Kingdom MHRA. Read here for more information on this milestone: https://brnw.ch/21wGuRc